Tamiflu endorsed for influenza prophylaxis by NICE
This week the National Institute for Clinical Excellence has approved oseltamivir (Tamiflu) for the prophylaxis of influenza in “at risk” patients.
NICE recommends that when the influenza A or influenza B virus is circulating
in the community, oseltamivir, a neuraminidase inhibitor, should be used
for post-exposure prophylaxis in “at risk” patients aged
13 years or older, who are not protected by vaccination and who can begin
prophylaxis within 48 hours.
At risk patients are defined as people who have chronic respiratory disease,
significant cardiovascular disease, chronic renal disease, diabetes,
or are immunocompromised or who are aged 65 years or over.
The guidance also recommends that the drug should be made available to
those living in residential care establishments whether or not they have
been vaccinated. The guidance advises use of oseltamivir in hospitals
at the discretion of the clinical staff in charge of wards where at risk
patients may be exposed to the influenza virus.
NICE advises that oseltamivir should not be used for the prevention of ’flu
in otherwise healthy people under 65 years of age, even if they have
been in contact with people with ’flu-like symptoms. The guidance
points out that vaccination is the most effective way of preventing illness
from influenza, and says oseltamavir is not a substitute for vaccination.
Amantidine (Lysovir) is not
recommended for either post-exposure or seasonal
prophylaxis of influenza (PJ, 1 March, p291).
The full NICE guidance can be accessed here.
News feature p400 |
